Multiple myeloma is a relatively rare type of blood cancer that causes uncontrollable multiplication of unhealthy plasma cells in the bone marrow. These cancerous plasma cells crowd out healthy ones and can severely inhibit the body’s immune response to infection.
As part of the Multiple Myeloma Research Foundation, we are contributing to the creation and annotation of one of the largest single cell datasets available for a single hematologic cancer. Our lab alone has helped sequence and align over one hundred individual CD138- bone marrow aliquots from patients diagnosed with Multiple Myeloma, and will be actively processing more over time.
We are working with the Immune Atlas Consortium under the MMRF, with partners at Beth Israel Deaconess Medical Center, Mayo Rochester, Mount Sinai School of Medicine, and Washington University in St. Louis, to characterize the bone marrow immune landscape of Multiple Myeloma from over 300 processed bone marrow aliquots. As an initial analysis, we are trying to establish and understand the baseline differences in immune composition and expression profiles between patients who go on to rapidly progress versus those with sustained non-progression. We are performing similar analyses accounting for multiple other factors, such as cytogenetic risk derived from whole genome sequencing, race, gender. Ultimately, we hope to better understand the factors within the immune environment which explain the rate of progression and success of therapy among newly diagnosed multiple myeloma patients.